Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Dutch firm argenx, J&J affiliate to collaborate on cancer therapy

December 3, 2018 9:12 AM
129 0

(Reuters) - Netherlands-based biopharmaceutical company argenx SE said it signed a deal with Cilag GmbH International, an affiliate of Johnson & Johnson’s Janssen Pharmaceutical Companies unit, to develop its Cusatuzumab drug in certain types of cancer.

The deal, which is potentially worth up to $1.6 billion, represents a global collaboration and licensing agreement for the cancer drug Cusatuzumab, the company said.

Read more

Share in social networks:

Comments - 0